In contrast, both luminal A (ER+ and/or PR+, HER2–, low Ki67) (Fig. 7b) and triple negative (Fig. 7e) breast cancer patients with low CREB3L1 mRNA expression had higher HRs (1.49 and 1.33, respectively) that were statistically significant (p <0.00001 and p <0.05, respectively). This evidence concerns the gene ERBB2 and breast carcinoma.